Healthcare / Drug Manufacturers - Specialty & GenericNYSE American
$0.76
-0.02 (-3.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-1.6M · quality 59.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$8M
P/E
0.3x
↓EV/EBITDA
N/A
•ROE
-28.2%
↓Gross Margin
62.4%
↑Debt/Equity
0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2016–2025 · 9 años de histórico normalizado
Revenue CAGR
+28.3%
FCF CAGR
—
FCF margin
-8.5%
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $19.2M · net income $-2.0M · FCF $-1.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | $19.2M | $19.2M | $19.5M | $24.2M | $35.4M | $44.5M | $41.9M | $23.7M | $459091.00 | $2.7M | $2.0M |
| Net Income | $-2.0M | $-2.0M | $-3.7M | $-22.9M | $-70.1M | $-23.4M | $12.6M | $-51.4M | $62834.00 | $-1.4M | $-3.9M |
| EBITDA | $-366668.00 | $-366668.00 | $-1.5M | $-6.3M | $-14.3M | $-18.6M | $-16.9M | $-14.5M | $-1.6M | $-1.3M | $-3.8M |
| EPS | -1.09 | -1.09 | -14.29 | -106.56 | -446.40 | -169.20 | 100.80 | 0.00 | 0.00 | — | — |
| Gross Margin | 62.4% | 62.4% | 61.6% | 62.0% | 63.1% | 67.4% | 63.0% | 61.4% | 77.3% | 113.7% | 20.3% |
| Operating Margin | -11.3% | -11.3% | -17.0% | -38.4% | -48.9% | -44.1% | -42.0% | -62.6% | -391.4% | -49.6% | -191.4% |
| Net Margin | -10.6% | -10.6% | -19.0% | -95.0% | -198.0% | -52.6% | 30.1% | -217.1% | 13.7% | -50.5% | -191.8% |
| Balance Sheet | |||||||||||
| Debt/Equity | 0.11 | 0.11 | 0.65 | 0.41 | 0.15 | 0.00 | 0.00 | — | — | — | — |
| Current Ratio | 2.83 | 2.83 | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||
| Free Cash Flow | $-1.6M | $-1.6M | $-642807.00 | $-4.6M | $-15.7M | $-14.4M | — | — | — | — | — |
| Returns | |||||||||||
| ROE | -28.2% | -28.2% | -188.5% | -254.0% | -223.0% | -22.7% | 15.9% | -136.6% | 0.4% | -32.9% | -1072.1% |
| Valuation | |||||||||||
| P/E | 0.31 | 0.31 | — | — | — | — | — | — | — | — | — |
| P/B | 0.43 | 0.43 | 1.04 | 0.21 | 0.46 | — | — | — | — | — | — |
| Growth & Yield | |||||||||||
| Revenue Growth | -1.5% | -1.5% | -19.3% | -31.8% | — | 6.2% | 77.1% | 5051.8% | -83.3% | 35.1% | — |
| EPS Growth | 92.4% | 92.4% | 86.6% | 76.1% | — | -267.9% | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-14.29 → -1.09
Residual
-14.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.